For research use only
| Cat No. | ABC-SC0100 |
| Product Type | Human Cancer Stem Cells |
| Cell Type | Stem Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Gallbladder |
| Disease | Bladder Cancer |
| Storage | Liquid Nitrogen |
Human Gall Bladderived Stem Cell; Frozen Vial and Plated cells are available.
HighQC™ Human Gall Bladder Derived Cancer Stem Cells (HGBCSCs) are isolated from patient-derived gallbladder carcinoma tissues. These cells express characteristic cancer stem cell markers including CD133, CD44, SSEA3/4, Oct4, confirmed via FACS analysis. They form spheroids under serum-free, low-attachment conditions and exhibit enhanced resistance to chemotherapeutic agents. GBCSCs demonstrate self-renewal, multipotency, and the capacity to regenerate heterogeneous tumor populations in vivo. These cells can differentiate into both epithelial and mesenchymal phenotypes, making them valuable for tumor progression and metastasis studies. Each lot undergoes rigorous screening and isolation procedures, and is rigorously tested to ensure it is free of contamination from HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.
| Product Code | HighQC™ Human Gall Bladder Derived Cancer Stem Cell, Human GB CSC, hGB-CSC, Human Gallbladder Progenitors |
| Species | Human |
| Cat.No | ABC-SC0100 |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Stem Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Gallbladder |
| Disease | Bladder Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Cancer Stem Cells |
HighQC™ Human Gall Bladder Derived Cancer Stem Cells provide a reliable in vitro model for studying gallbladder carcinogenesis, epithelial-mesenchymal transition (EMT), and cancer stem cell-targeted therapies. These cells are ideal for drug resistance screening, biomarker validation, and elucidating molecular mechanisms of tumor relapse and metastasis. Their properties as gallbladder tumor-initiating cells also support the development of immunotherapeutic and gene-targeting approaches for aggressive biliary tract cancers.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).